{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-004906","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2021-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.770210+00:00","generated_at":"2026-06-28T05:28:25.673462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aura Biosciences Q3 net loss $8.8M; AU-011 data and IPO highlight quarter","bullets":["Net loss $8.8M for Q3 2021 vs $3.6M YoY; R&D expenses $6.4M (up from $2.9M).","Cash $81.8M at Sep 30; IPO raised $86.9M gross in Nov 2021 at $14.00/share.","Final Phase 1b/2 data: 64% tumor control, 71% visual acuity preservation for AU-011 in choroidal melanoma.","Plans to start AU-011 pivotal program H2 2022; Phase 1a in NMIBC expected H2 2022.","Added Antony Mattessich to board and Chris Primiano as CBO in September 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-004906","json":"https://secwatch.observer/filing/0000950170-21-004906.json","markdown":"https://secwatch.observer/filing/0000950170-21-004906.md","text":"https://secwatch.observer/filing/0000950170-21-004906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017021004906/0000950170-21-004906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017021004906/aura-20211124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T05:28:25.673462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}